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Abstract 
Purpose: To address the hypothesis that liver steatosis causes systemic insulin resistance, 
we sought to determine the liver histological feature that most strongly contributes to 
insulin resistance in patients with nonalcoholic fatty liver disease (NAFLD).
Methods: Liver biopsy specimens were obtained from 131 patients with clinically 
suspected NAFLD.  The stage, grade of nonalcoholic steatohepatitis (NASH), and levels 
of steatosis were scored and analyzed in relation to the homeostasis model assessment of 
insulin resistance (HOMA-IR), and the metabolic clearance rate (MCR) measured using 
the glucose clamp method. 
Results: In the univariate analysis, the degree of hepatic steatosis (r=0.458, p<0.001), 
stage (r=0.360, p<0.001), and grade (r=0.349, p<0.01) of NASH were significantly 
correlated with the HOMA-IR.  Multiple regression analysis adjusting for age, sex, body 
mass index, and each other’s histological score showed that steatosis was significantly 
and independently associated with HOMA-IR (coefficient=1.42, p<0.001), but not the 
stage (coefficient=0.33, p=0.307) or grade (coefficient=0.67, p=0.134) of NASH.  
Similar independent relationships were observed between steatosis and MCR, but the 
relationship was weaker (coefficient=-0.98, p=0.076).
Conclusions: Steatosis of the liver, but not the stage or the grade of NASH, is associated 
with insulin resistance in patients with NAFLD. 
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Introduction 
Nonalcoholic fatty liver disease (NAFLD) is often associated with various 
metabolic abnormalities, including obesity,1,2 type 2 diabetes,1-4 and dyslipidemia,3-7 all 
of which are closely associated with insulin resistance and are important risk factors for 
cardiovascular diseases.  Insulin resistance, which can be accurately measured using the 
glucose clamp method,8 is a condition in which the cells of the body become resistant to 
the effects of insulin, resulting in a decreased response to a given amount of insulin.  This 
condition is associated with various underlying metabolic abnormalities, including 
obesity, type 2 diabetes, dyslipidemia, and hypertension.9,10  Insulin resistance is also 
associated with NAFLD,11-15 which can range from a simple fatty liver to nonalcoholic 
steatohepatitis (NASH).16-18  This latter condition can progress to cirrhosis of the liver 
and hepatocellular carcinoma.19-24
The particular histological findings of NAFLD that are associated with the 
metabolic abnormalities have not been elucidated fully.11, 12, 25-31  Steatosis of the liver has 
been reported to be associated with body mass index (BMI),25 waist circumference,11 
hypertension,11,25 glucose intolerance,11,25 dyslipidemia,11,25 and insulin resistance.11,12  
Furthermore, experiments have demonstrated that hepatic steatosis per se causes insulin 
resistance in vivo.32-35  Nevertheless, the association between the degree of hepatic 
fibrosis and metabolic abnormalities is still controversial.  Some reports suggest that, in 
NAFLD patients, fibrosis is associated with insulin resistance and higher rates of diabetes, 
 - 4 - 
dyslipidemia, and hypertension,11,12,25-29 whereas other reports suggest that the stage of 
fibrosis is not significantly associated with metabolic abnormalities.30,31  These 
discrepant findings may be due to differences in the severity of obesity and the 
complicated metabolic abnormalities of the patients in these studies. 
To test the hypothesis that liver steatosis causes systemic insulin resistance, we 
sought to determine the liver histological feature that most strongly contributes to insulin 




The study subjects were 131 patients with clinically suspected NAFLD, who were 
recruited consecutively between 1997 and 2004 at Kanazawa University Hospital, Japan.  
Twenty of the patients were referred to our hospital for evaluation of liver injury, while in 
the remaining 111 patients, the liver injury was identified during the treatment of other 
metabolic disorders, such as diabetes mellitus and obesity.  Fatty liver was clinically 
diagnosed based on ultrasound examination showing an increase in hepato-renal contrast, 
defined as the ratio of the hepatic to the kidney echo levels of >1.0, also known as a 
‘bright liver.’  In each patient, all other liver disorders were excluded, including viral 
hepatitis B and C, primary biliary cirrhosis, autoimmune hepatitis, sclerosing cholangitis, 
hemochromatosis, Wilson’s disease, drug-induced liver injury, and biliary obstruction.  
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All patients reported drinking less than 20 g/day of ethanol. 
The 131 patients had a mean age of 48 years and a mean BMI of 27.4 kg/m2 (Table 
1).  Of the 131 patients, 108 (82%) had type 2 diabetes according to the American 
Diabetes Association criteria.36  Among these patients, 54 were treated with diet alone; 
the remainder were treated with an α-glucosidase inhibitor (n=14), a rapid-acting insulin 
secretion agent (nateglinide, n=11), or a pre-meal rapid-acting insulin analogue (n=40).  
Hypertension and dyslipidemia were defined according to the definition of the National 
Cholesterol Education Program – Adult Treatment Panel-III metabolic syndrome.37  
Hypertension was observed in 65 patients (50%), 36 of whom had been treated with 
antihypertensive agents.  High triglyceride levels were observed in 47 (36%) patients, and 
low HDL levels were observed in 33 (25.2%), 30 of whom had been treated with statins.  
None of the patients were on medication, such as sulfonylureas, thiazolidinediones, 
metformins, vitamin E, and ursodeoxycholic acid, that could influence the fasting 
insulin/glucose levels or induce histological changes in the liver.  The patients gave their 
written informed consent for this study, which was approved by the hospital ethics board. 
 
Laboratory studies 
After an overnight fast, venous blood samples were withdrawn from each patient.  
Serum samples were assayed for total cholesterol, triglycerides, HDL cholesterol, and 
insulin.  Plasma samples were assayed for glucose. 
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 Evaluation of insulin sensitivity 
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated 
using the formula, HOMA-IR = [fasting insulin (μU/ml) × fasting plasma glucose 
(mmol/l)]/22.5.38
Insulin sensitivity was also evaluated using the glucose clamp method8 in 46 
patients (35 diabetic and 11 non-diabetic patients).  These patients did not receive any 
medication on the morning of the examination.  At approximately 9 a.m., after an 
overnight fast of at least 10 hours, an intravenous catheter was placed in an antecubital 
vein of each subject for infusion, while a second catheter was placed in the contralateral 
hand for blood sampling.  The euglycemic hyperinsulinemic clamp technique was done 
using an artificial pancreas (model STG-22; Nikkiso, Tokyo, Japan), as described 
previously.39  A solution of 0.8 U/ml insulin (Novolin R: Novo Nordisk, Copenhagen, 
Denmark) in normal saline was allowed to remain in the intravenous lines for at least 15 
min, and the lines were then flushed before starting the insulin infusion.  Insulin was 
infused at a rate of 3.0 mU/kg/min, resulting in a steady state insulin concentration of 
290.3±61.7 μU/ml (mean±SD).  Blood glucose levels were determined continuously 
during the clamp study and maintained by variable-rate infusion of 20% glucose at 
fasting levels or at 100 mg/dl, whichever was higher.  The steady state period was 
maintained for 30 min or longer, during which the coefficients of variation for blood 
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glucose and the glucose infusion rate were each less than 5%.  Glucose levels reached 
during the clamp study were 91.3±15.5 mg/dl.  Insulin sensitivity was expressed as the 
glucose metabolic clearance rate (MCR) in mg/kg/min.  The mean MCR in healthy 
subjects (n=9, age 26.6±2.9 years, BMI 22.3±2.1 kg/m2) was 13.5±3.4 mg/kg/min. 
 
Pathology 
After obtaining informed consent, liver biopsy specimens were obtained from all 
131 patients, 59 of whom had elevated aminotransferase levels on admission for the liver 
biopsy and 72 had normal aminotransferase levels at the time of biopsy, but a history of 
elevated aminotransferase levels before admission.  Each specimen was stained with 
hematoxylin-eosin and silver reticulin stains and histologically examined by one 
pathologist who was blinded to the patient’s clinical condition and biochemical data.  
Each biopsy was scored according to the standard criteria for grading and staging of 
NASH proposed by Brunt et al.40,41  Steatosis of the liver was also scored from 0 to 3 (0, 
none; 1, <33%; 2, 33-66%; 3, >66%) according to the modified criteria of Brunt et al.40,41
 
Statistical analyses 
The correlation coefficients between pairs of indices were calculated, with p<0.05 
considered statistically significant.  Multiple linear regression analysis was used to 
calculate age-, sex-, and BMI-adjusted coefficients between each histological score and 
 - 8 - 
insulin resistance.  The t-statistic was used to compare the strength of the relationship. 
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Results 
The characteristics of the study subjects and the number of patients with each 
histological score are shown in Table 1.  We found that the mean HOMA-IR was higher 
and the mean MCR was lower in NAFLD patients than in normal subjects.  Scores of the 
stage and grade of NASH were strongly correlated (r=0.570, p<0.001), and each was 
weakly correlated with the hepatic steatosis score (stage, r=0.389, p<0.001; grade, 
r=0.397, p<0.001), suggesting that steatosis and inflammation or fibrosis are pathological 
attributes of patients with NAFLD. 
We evaluated the association between markers for insulin resistance and 
histological scores of the liver.  In univariate analysis (Table 2), the degree of hepatic 
steatosis, stage, and grade of NASH were significantly correlated with HOMA-IR.  The 
degree of hepatic steatosis and grade of NASH were significantly correlated with MCR.
Multiple linear regression models were computed to assess the age-, sex-, and 
BMI-adjusted relative influence of each histological score on insulin resistance (Table 3). 
 Steatosis, as well as the stage and grade of NASH, was associated with HOMA-IR, even 
after adjusting for age, sex, and BMI in the multiple regression analysis.  When these 
three histological scores were adjusted for each other in a model that included all three 
simultaneously, only the steatosis score was associated with HOMA-IR, and the 
associations of the stage and grade of NASH with HOMA-IR were not significant.  A 
similar independent relationship was observed between steatosis of the liver and MCR, 
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but the relationship was weaker. 
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Discussion 
Patients with NAFLD have features of the insulin resistance-associated metabolic 
syndrome, which puts them at increased risk for developing cardiovascular diseases.13-15  
Patients with advanced NASH have also been reported to have a higher intra-abdominal 
fat mass, a higher prevalence of hypertriglyceridemia, a low HDL-cholesterol, and more 
severe insulin resistance than healthy subjects matched for age, sex, race, and BMI.27  
However, the association between the degree of the histological changes, especially liver 
fibrosis, and metabolic abnormalities is still controversial in NAFLD patients.11,12,25-31  
When we investigated the HOMA-IR and MCR calculated by using the glucose clamp 
method, which is the gold standard for evaluating insulin resistance,8 we found that 
insulin resistance was increased in NAFLD patients.  On examining the relationship 
between insulin resistance and NAFLD histological scores, we found that insulin 
resistance was associated with the severity of hepatic steatosis, but not with the severity 
of inflammation or fibrosis after adjusting for the hepatic steatosis score. 
Our findings differ from those of a recent report showing that metabolic syndrome 
is associated with advanced NASH.26  In that report, patients with advanced NASH had a 
higher BMI than patients who have a simple fatty liver.  Since a higher BMI itself is 
strongly associated with insulin resistance and metabolic abnormalities, metabolic 
abnormalities associated with liver pathology should only be determined after adjusting 
for BMI.  In fact, our study showed that BMI was independently associated with both 
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liver steatosis and the stage of NASH.  When we evaluated the association between the 
histological scores of the liver and insulin sensitivity using multiple regression models, 
the hepatic steatosis score was associated with insulin sensitivity, even after adjusting for 
age, sex, BMI, and each other’s histological score, whereas the association between the 
stage or grade of NASH and insulin resistance was no longer significant.  These findings 
clearly indicate that only the degree of hepatic steatosis is an independent predictor of 
insulin resistance in patients with NAFLD. 
We evaluated the insulin sensitivity using two methods: HOMA-IR and MCR.  In 
our results, steatosis of the liver was more strongly associated with HOMA-IR than MCR.  
In this study, MCR was measured only in 46 of 131 NAFLD patients; therefore, the 
statistical power would not be sufficient to detect a significant relationship.  Furthermore, 
organ-specific insulin resistance may also influence the results.  MCR is a marker for 
splanchnic insulin resistance, mainly muscle insulin resistance.8  By contrast, HOMA-IR 
is considered a marker for hepatic insulin resistance because HOMA-IR is calculated 
using fasting glucose and insulin levels, which are determined by fasting hepatic glucose 
production.  Therefore, hepatic steatosis may be associated more strongly with the index 
of ‘hepatic’ insulin resistance. 
Recently, we used cDNA microarrays to characterize the changes that occur in the 
moderate fatty liver of type 2 diabetic patients.42,43  In the livers of patients with type 2 
diabetes, the genes for mitochondrial oxidative phosphorylation and gluconeogenesis are 
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up-regulated, and are associated with fasting hyperglycemia.43  These findings, together 
with our results, suggest that hepatic steatosis per se causes insulin resistance in patients 
with NAFLD. 
The main limitation of this study is that most of the study subjects were diabetic 
patients.  Therefore, insulin resistance may be greater in these study subjects than in the 
general population, and this may have influenced the results.  A large-scale prospective 
study is needed to confirm our conclusion and to clarify the prognosis of patients with 
NAFLD. 
In this paper, we showed that, steatosis of the liver per se is an independent 
predictor for insulin resistance in patients with NAFLD.  Simple fatty liver has been 
considered as benign condition compared with advanced NASH, but we should regard the 
patients with liver steatosis, irrespective with the degree of inflammation and fibrosis, as 
high-risk group for cardiovascular disease because they have higher insulin resistance.  
To prevent cardiovascular disease, patients with severe fatty liver should be evaluated for 
insulin resistance-associated metabolic abnormalities and monitored intensively to 
reduce the occurrence of risk factors for atherosclerosis. 
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 Table 1. Clinical characteristics of the study subjects 
(Male n=84; Female n=47; Total, n=131) 
  Mean ± SD Normal range 
Age (years) 48±14  
Body mass index (kg/m2) 27.4±5.5 18-25 
AST (IU/L) 39.4±38.5 10-48 
ALT (IU/L) 62.1±74.6 3-50 
Fasting plasma glucose (mg/dl) 127±40 70-110 
Basal insulin (μU/ml) 12.0±11.7 <20 
HbA1C (%) 6.9±1.8 4.3-5.8 
Total cholesterol (mg/dl) 205±44 132-220 
Triglycerides (mg/dl) 139±77 32-150 
HDL cholesterol (mg/dl) 48±13 40-97 
HOMA-IR 3.4±3.2 <2.0 
Metabolic clearance rate (mg/kg/min)* 6.1±2.7 9.9-16.9 
Histological scores  
           Stage (0/1/2/3/4) 22/45/38/23/3  
           Grade (0/1/2/3) 48/61/19/3  
           Steatosis (0/1/2/3) 7/82/27/15   
HOMA-IR, homeostasis model assessment of insulin resistance. 
* Metabolic clearance rate was measured in a part of the subjects (n=46). 
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Table 2. Univariate correlation between histological scores and insulin resistance 
  HOMA-IR Metabolic clearance rate 
  (n=131) (n=46) 
Steatosis 0.46 *** -0.42  **
Stage 0.36 *** -0.17   
Grade 0.35 *** -0.30  *
HOMA-IR, homeostasis model assessment of insulin resistance. 
*p<0.05, **p<0.01, *** p<0.001 
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Table 3. Age-, sex-, and BMI-adjusted association between insulin resistance and histological 
changes of the liver 
 HOMA-IR (n=131) Metabolic clearance rate (n=46) 
  Coefficient t-statistic p Coefficient t-statistic p 
Steatosis 1.81  4.59  <0.001 -1.23  -2.62  0.012 
       
Stage 0.90  3.15  0.002 -0.23  -0.62  0.540  
       
Grade 1.37  3.51  0.001 -1.07  -2.26  0.029 
       
Steatosis* 1.42  3.40  <0.001 -0.98  -1.82  0.076 
Stage 0.33  1.03  0.307 0.35  0.85  0.401 
Grade 0.67  1.51  0.134 -0.86  -1.46  0.151 
HOMA-IR, homeostasis model assessment of insulin resistance. 
All models are adjusted for age, sex, and BMI by multiple linear regression. 
*Three histological scores are included in the same model. 
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